BR9708343A - Anticorpo composição linhagem de células método para determinar a presença de proteína de erbB3 e kit - Google Patents

Anticorpo composição linhagem de células método para determinar a presença de proteína de erbB3 e kit

Info

Publication number
BR9708343A
BR9708343A BR9708343A BR9708343A BR9708343A BR 9708343 A BR9708343 A BR 9708343A BR 9708343 A BR9708343 A BR 9708343A BR 9708343 A BR9708343 A BR 9708343A BR 9708343 A BR9708343 A BR 9708343A
Authority
BR
Brazil
Prior art keywords
erbb3
kit
determining
erbb3 protein
cell line
Prior art date
Application number
BR9708343A
Other languages
English (en)
Inventor
Robert Akita
Mark Sliwkowski
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24500380&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9708343(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BR9708343A publication Critical patent/BR9708343A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
BR9708343A 1996-03-27 1997-03-07 Anticorpo composição linhagem de células método para determinar a presença de proteína de erbB3 e kit BR9708343A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62403696A 1996-03-27 1996-03-27
PCT/US1997/003546 WO1997035885A1 (en) 1996-03-27 1997-03-07 ErbB3 ANTIBODIES

Publications (1)

Publication Number Publication Date
BR9708343A true BR9708343A (pt) 1999-08-03

Family

ID=24500380

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9708343A BR9708343A (pt) 1996-03-27 1997-03-07 Anticorpo composição linhagem de células método para determinar a presença de proteína de erbB3 e kit

Country Status (15)

Country Link
EP (2) EP0896586B2 (pt)
JP (1) JP3925943B2 (pt)
CN (1) CN1214044C (pt)
AT (1) ATE342283T1 (pt)
AU (1) AU727082B2 (pt)
BR (1) BR9708343A (pt)
CA (1) CA2246429C (pt)
DE (1) DE69736806T3 (pt)
DK (1) DK0896586T4 (pt)
ES (1) ES2274537T5 (pt)
IL (2) IL126303A (pt)
NZ (1) NZ331360A (pt)
PT (1) PT896586E (pt)
WO (1) WO1997035885A1 (pt)
ZA (1) ZA972554B (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6417168B1 (en) * 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
US6627196B1 (en) 1999-08-27 2003-09-30 Genentech, Inc. Dosages for treatment with anti-ErbB2 antibodies
AU2008200654B2 (en) * 2001-08-09 2010-04-29 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Inhibitors of HER3 activity
EP1283053A1 (en) * 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
CN100424175C (zh) 2002-03-26 2008-10-08 上海泽生科技开发有限公司 ErbB-3 用于肿瘤治疗的方法和组合物
HUP0600340A3 (en) 2002-07-15 2011-06-28 Genentech Inc Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies
KR101200133B1 (ko) 2004-06-01 2012-11-13 제넨테크, 인크. 항체 약물 접합체 및 방법
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
CA2580141C (en) 2004-09-23 2013-12-10 Genentech, Inc. Cysteine engineered antibodies and conjugates
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
US20100047829A1 (en) 2006-11-28 2010-02-25 U3 Pharma Gmbh Activated her3 as a marker for predicting therapeutic efficacy
EP3248617A3 (en) 2007-02-16 2018-02-21 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof
EP2318548B1 (en) 2008-08-15 2013-10-16 Merrimack Pharmaceuticals, Inc. Methods and systems for predicting response of cells to a therapeutic agent
EP2417159A1 (en) 2009-04-07 2012-02-15 Roche Glycart AG Bispecific anti-erbb-3/anti-c-met antibodies
TWI630916B (zh) 2009-11-13 2018-08-01 第一三共歐洲公司 供治療或預防人表皮生長因子受體－３（ｈｅｒ－３）相關疾病之藥料和方法
JP6184695B2 (ja) 2009-12-04 2017-08-23 ジェネンテック， インコーポレイテッド 多重特異性抗体、抗体アナログ、組成物、及び方法
MY161909A (en) 2009-12-22 2017-05-15 Roche Glycart Ag Anti-her3 antibodies and uses thereof
SG183532A1 (en) 2010-03-11 2012-09-27 Merrimack Pharmaceuticals Inc Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
ES2566602T3 (es) * 2010-04-09 2016-04-14 Aveo Pharmaceuticals, Inc. Anticuerpos anti-ErbB3
CN103153339B (zh) 2010-05-27 2021-05-04 根马布股份公司 针对her2表位的单克隆抗体
CA3051311A1 (en) 2010-05-27 2011-12-01 Genmab A/S Monoclonal antibodies against her2
AU2011274510A1 (en) 2010-07-09 2013-01-24 Exelixis, Inc. Combinations of kinase inhibitors for the treatment of cancer
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
EP2635604B1 (en) * 2010-11-01 2016-11-30 Symphogen A/S Pan-her antibody composition
SI2699602T1 (sl) 2011-04-19 2017-06-30 Merrimack Pharmaceuticals, Inc. Bispecifična protitelesa anti-igf-1r in anti-erbb3
JP2014514314A (ja) 2011-04-20 2014-06-19 ゲンマブ エー／エス Ｈｅｒ２およびｃｄ３に対する二重特異性抗体
EP2760893B1 (en) 2011-09-30 2018-09-12 Regeneron Pharmaceuticals, Inc. Anti-erbb3 antibodies and uses thereof
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
AU2012318541B2 (en) 2011-10-06 2018-04-12 Aveo Pharmaceuticals, Inc. Predicting tumor response to anti-ERBB3 antibodies
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
JP6149042B2 (ja) * 2011-11-09 2017-06-14 ザ ユーエービー リサーチ ファンデーション Ｈｅｒ３抗体およびその使用
RU2620068C2 (ru) 2011-11-23 2017-05-22 МЕДИММЬЮН, ЭлЭлСи Связывающие молекулы, специфичные по отношению к her3, и их применения
KR102083957B1 (ko) * 2011-12-05 2020-03-04 노파르티스 아게 표피 성장 인자 수용체 3 (her3)에 대한 항체
KR20150063565A (ko) * 2012-11-08 2015-06-09 에프. 호프만-라 로슈 아게 Her3의 베타-헤어핀 및 her4의 베타-헤어핀에 결합하는 항-her3/her4 항원 결합 단백질
WO2014072306A1 (en) 2012-11-08 2014-05-15 F. Hoffmann-La Roche Ag Her3 antigen binding proteins binding to the beta-hairpin of her3
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
WO2015048008A2 (en) 2013-09-24 2015-04-02 Medimmune, Llc Binding molecules specific for her3 and uses thereof
WO2015100459A2 (en) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
US10745490B2 (en) 2014-04-11 2020-08-18 Celldex Therapeutics, Inc. Anti-ErbB antibodies and methods of use thereof
WO2015173250A1 (en) 2014-05-14 2015-11-19 F. Hoffmann-La Roche Ag Anti-her3 antibodies binding to the beta-hairpin of her3
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
TW202227504A (zh) * 2020-10-15 2022-07-16 大陸商上海翰森生物醫藥科技有限公司 抗ｅｒｂｂ３抗體或其抗原結合片段及其醫藥用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5183884A (en) * 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
AU662311B2 (en) * 1991-02-05 1995-08-31 Novartis Ag Recombinant antibodies specific for a growth factor receptor
AU675929B2 (en) * 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
WO1993021319A1 (en) * 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
AU6527894A (en) * 1993-03-30 1994-10-24 Trustees Of The University Of Pennsylvania, The Prevention of tumors with monoclonal antibodies against (neu)
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis

Also Published As

Publication number Publication date
AU727082B2 (en) 2000-11-30
NZ331360A (en) 2000-03-27
EP0896586B1 (en) 2006-10-11
DK0896586T3 (da) 2007-02-19
CA2246429C (en) 2007-07-24
DE69736806T3 (de) 2015-10-08
DE69736806T2 (de) 2007-08-09
ATE342283T1 (de) 2006-11-15
EP1728802A2 (en) 2006-12-06
AU2071197A (en) 1997-10-17
EP1728802A3 (en) 2006-12-13
ES2274537T3 (es) 2007-05-16
PT896586E (pt) 2007-01-31
ES2274537T5 (es) 2015-09-14
JP2000508526A (ja) 2000-07-11
WO1997035885A1 (en) 1997-10-02
IL126303A (en) 2002-05-23
IL126303A0 (en) 1999-05-09
CA2246429A1 (en) 1997-10-02
DE69736806D1 (de) 2006-11-23
CN1214695A (zh) 1999-04-21
ZA972554B (en) 1998-09-25
DK0896586T4 (en) 2015-08-24
CN1214044C (zh) 2005-08-10
EP0896586A1 (en) 1999-02-17
EP0896586B2 (en) 2015-05-20
JP3925943B2 (ja) 2007-06-06

Similar Documents

Publication Publication Date Title
BR9708343A (pt) Anticorpo composição linhagem de células método para determinar a presença de proteína de erbB3 e kit
ATE412432T1 (de) Internalisierende erbb2 antikörper
EP0930366A3 (en) Binding domains in delta proteins
DE69619493D1 (de) Polypeptid-dendrimer komplexe
DE69429925T2 (de) METHODE ZUR BINDUNG VON MATERIAL AN DAS Beta-AMYLOID-PEPTID
DE60334141D1 (de) VERÄNDERUNG VON FcRn-BINDUNGSAFFINITÄTEN ODER VON SERUMHALBWERTSZEITEN VON ANTIKÖRPERN MITTELS MUTAGENESE
PT1135498E (pt) Variantes de anticorpos com maior afinidade de ligação em comparação com os anticorpos parentais
AU2152299A (en) Multivalent antigen-binding proteins
WO2002090983A3 (de) Quantitaver einschritt immuntest in lyophilisierter form
WO2001040307A8 (de) Antikörper gegen signal-regulator-proteine
IL154000A (en) A method that uses antibodies to diagnose arthritis
ATE193600T1 (de) Verfahren zur stabilisierung von enzym-konjugaten
WO2004099366A3 (en) Context sensitive parallel optimization of zinc finger dna binding domains
NZ336781A (en) Fibronectin binding protein compositions, antibodies thereto, and methods of use
AU5326198A (en) Synthetic biepitope compounds which can be used as standards in the biological assays of troponin I
AU2726388A (en) Determination method, use and components
CA2589421A1 (en) Erbb3 antibodies
WO1999024835A3 (en) An immunoassay for procollagen-iii-c-terminal propeptide
MXPA02011906A (es) Ensayo, equipo y procedimiento a base de esferas no lavables.
DE69220863T2 (de) Denaturierte transportproteine zur verbesserung von enzymgebundenen immunoassays (elisa)
DK0889907T3 (da) Monoklonale antistoffer, som binder humant væksthormon (hGH)
GB2333295A (en) Modified protein G and fragments thereof
HUP0003029A2 (hu) Ankrod specifikus monoklonális antitestek, antitestfragmentumok, keverékeik és alkalmazásuk

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: SUSPENSAO DO ANDAMENTO DO PEDIDO DE PATENTE PARA QUE SEJA COMPLEMENTADA A RETRIBUICAO EQUIVALENTE AO PEDIDO DE EXAME DE 36 (TRINTA E SEIS) REIVINDICACOES, VISTO QUE A RETRIBUICAO PAGA ATRAVES DA PETICAO N SP003288, DE 20000131, REFERE-SE A 21 (VINTE E UMA) REIVINDICACOES.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 37 DA LEI 9.279/96, INDEFIRO O PRESENTE PEDIDO COM BASE NOS ARTS. 24 E 25 DA LEI NO 9.279/96

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.